Positive Outlook for Carl Zeiss Meditec
Carl Zeiss Meditec AG is to continue the path of focus and growth initiated a year ago with Dr. Michael Kaschke (52) as President and CEO. Dr. Kaschke has resigned his suspended membership of the Supervisory Board.
"The entire Supervisory Board is impressed by the results achieved. With a targeted strategic direction, it has proved possible under Dr. Kaschke's leadership to keep the company on a path of success and growth even in these difficult economic times. For that reason, we will continue to put our trust in continuity," explained Dr. Markus Guthoff, Chairman of the Supervisory Board of Carl Zeiss Meditec AG.
"With a targeted focus on innovation, customer orientation and growth markets, we are posting pleasing results even in the context of the current economic situation. We will continue to invest in future-oriented topics. We can confirm our statement that Carl Zeiss Meditec will continue to grow while keeping the profitability stable and increasing it in the medium term. Compared to last year, we anticipate revenue growth of at least 5 percent in this current adverse year," concluded Dr. Michael Kaschke, President and CEO of Carl Zeiss Meditec AG.
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.